Ecke TH, Lenk SV, Schlechte HH, Loening SA
Tissue Polypeptide Antigen (TPA) in Comparison with Mutations of Tumour Suppressor Gene P53 (TP53) in Patients with Bladder Cancer
Anticancer Res 23: 957-962, 2003

Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA
Four Tumour Markers for Urinary Bladder Cancer - Tissue Polypeptide Antigen (TPA), HER-2/neu (ERB B2), Urokinase-type Plasminogen Activator Receptor (uPAR) and TP53 Mutation
Anticancer Res 25(1B): 635-642, 2005

Ecke TH, Lenk SV,  Schlechte HH, Loening SA
Mutations of tumorsuppressor gene p53 (TP53) in tumour tissue and cellular urine sediments in urinary bladder cancer
Gene Ther Mol Biol 9: 393-400, 2005

Ecke TH, Bartel P, Koch S, Ruttloff J, Theissig F
Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium
Oncol Rep 16(6):1381-1388, 2006

Ecke TH, Schlechte HH, Hübsch A, Lenk SV, Schiemenz K, Rudolph BD, Miller K
TP53 Mutation in Prostate Needle Biopsies – Comparison with Patients Follow-up
Anticancer Res 27(6): 4143-4148, 2007

Ecke TH, Sachs MD, Lenk SV, Loening SA, Schlechte HH
TP53 gene mutations as an independent marker for urinary bladder cancer progression
Int J Mol Med 21: 655-661, 2008

Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M
Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability
World J Urol. 26(3): 243-250, 2008

Ecke TH, Gunia S, Bartel P, Hallmann S, Koch S, Ruttloff J
Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire
Urol Oncol  26(5): 474-478, 2008

Ecke TH, Schlechte HH, Gunia S, Lenk SV, Loening SA
Body Mass Index (BMI) and mutations of Tumoursuppressor-Gene p53 (TP53) in patients with urinary bladder cancer
Urol Oncol 26(5): 470-473, 2008

Ecke TH
Focus on urinary bladder cancer markers: a review
Minerva Urol Nefrol 60(4): 237-246, 2008

Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Med Oncol. 2009 Apr 28.

Ecke TH, Gerullis H, Bartel P, Koch S, Ruttloff J
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium
Minerva Urol Nefrol. 61(1):1-8, 2009

Ecke TH, Gerullis H, Bartel P, Koch S, Ruttloff J
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium
Minerva Urol Nefrol: 61:249-256, 2009